Alzheimer's disease
Alzheimer s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasi...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , |
| Format: | Livre numérique |
| Sprache: | Anglais |
| Veröffentlicht: |
Berlin, Heidelberg :
Springer Berlin Heidelberg
[20..].
Cham : Springer Nature |
| Ausgabe: | 1st ed. 2008. |
| Schriftenreihe: | Topics in Medicinal Chemistry
2 |
| Online Zugang: | Accès sur la plateforme de l'éditeur Accès sur la plateforme Istex Accès Université d'Orléans Accès INSA CVL |
| Anmerkung: |
Archives Springer e-books (Licence nationale) Archives Springer e-books (Licence nationale) |
| Autres localisations: | Voir dans le Sudoc |
| Variante du titre: | With contributions by numerous experts |
| Edition sous un autre format: | • Alzheimer's Disease, Texte imprimé, 9783540742289 • Alzheimer's Disease, Texte imprimé, 9783642093548 • Alzheimer's Disease, Texte imprimé, 9783540842231 • Alzheimer's Disease, Texte imprimé, 9783540742289 |
| Zusammenfassung: | Alzheimer s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors). This volume will first review existing cholinesterase inhibitors prescribed for AD patients followed by some target mechanisms with ongoing clinical trials. It offers a glimpse of what our future medicine cabinets may look like for AD patients. It also provides an interesting read on why and how current medicines for other indications could potentially be used to treat AD |
|---|---|
| Beschreibung: | Archives Springer e-books (Licence nationale) Archives Springer e-books (Licence nationale) |
| ISBN: | 9783540742296 |
| ISSN: | 1862-247X |
| Zugangseinschränkungen: | Accès en ligne pour les établissements français bénéficiaires des licences nationales Accès soumis à abonnement pour tout autre établissement Conditions particulières de réutilisation pour les bénéficiaires des licences nationales. https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 |